# Week in Review: Clinical Breakthroughs in Metabolism, Cannabinoids, Primary Care, and AI (10/23 – 10/30/26) > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/week-in-review-2026-10-30/ > **Published:** 2026-10-30T15:15:44-04:00 | **Last Modified / Clinically Audited:** 2026-10-30T15:15:44-04:00 > **Clinical Summary:** Clinical Evidence Radar The Medical Frontier: Week in Review (10/23 – 10/30/26) Evidence-grounded briefing ordered dynamically by clinician impact index, practice utility, and patient resonance. ⚡ Executive Clinical Evidence Summary (2026 Direct Takeaway) This weekly medical synthesis confirms incretin (GLP-1/GIP) therapies lower glycemic burden and severe hypoglycemia in type 2 diabetes while necessitating resistance protocols […] --- Clinical Evidence Radar The Medical Frontier: Week in Review (10/23 – 10/30/26) Evidence-grounded briefing ordered dynamically by clinician impact index, practice utility, and patient resonance. ⚡ Executive Clinical Evidence Summary (2026 Direct Takeaway) This weekly medical synthesis confirms incretin (GLP-1/GIP) therapies lower glycemic burden and severe hypoglycemia in type 2 diabetes while necessitating resistance protocols against lean muscle loss. Simultaneously, preclinical data illustrates dose-dependent biphasic THC impacts on affiliative social behavior, general practice models establish symptom-clustering to distinguish bipolar from unipolar depression, and clinical AI integration demands vigilant physician bedside oversight. Clinical Evidence Translation Guideline Inertia vs. Individualized Preventive Care Mainstream Media Narrative Standardized population guidelines represent the definitive gold standard for every individual patient. What the Evidence Shows Population guidelines reflect epidemiological compromises, often trailing cutting-edge metabolic, chronobiological, and deprescribing science by 5 to 10 years. What’s up, Doc? True preventive medicine requires treating the unique biological individual in front of you, not the statistical mean of a 10-year-old cohort. 📊 2026 Clinical Evidence Synthesis Matrix Medical Pillar Featured Study & Rigor What’s up, Doc? (Bedside Rule) Primary Care & Preventive Medicine **Randomized Controlled Trial of Salt and Amiloride on Vascular Stiffness in ADPKD.**Kidney international reports • LEVEL 1 EVIDENCE • 9.8/10 Metabolic & Longevity Science **External validation of artificial intelligence-guided electrocardiogram (AI-ECG) in detecting asymptomatic left ventricular dysfunction: A systematic review and meta-analysis.**American journal of preventive cardiology • LEVEL 1 EVIDENCE • 9.5/10 Medical Innovation & Clinical Tech **Evaluating a multi-vaccine respiratory immunization strategy involving SARS-CoV-2, pneumococcal, and influenza vaccines in adults: A randomized, open-label, multicenter, controlled, non-inferiority Phase IV trial in China.**Human vaccines & immunotherapeutics • LEVEL 2 EVIDENCE • 9.2/10 Cannabinoid Science & ECS **DIalysis Symptom COntrol-Pruritus Outcome Trial (DISCO-POT): A Multicenter Randomized Blinded Placebo Controlled Crossover Trial.**Kidney medicine • EXPLORATORY • 9.0/10 Primary Care & Preventive Medicine 01 • MOST POPULAR LEVEL 1 EVIDENCE • 9.8/10 [Randomized Controlled Trial of Salt and Amiloride on Vascular Stiffness in ADPKD.](https://doi.org/10.1016/j.ekir.2026.107110?utm_source=weekly_review&utm_medium=ranked_feed&utm_campaign=2026-10-30&utm_content=rank1_randomized-controlled-trial-of-salt) **Source:** Kidney international reports • **Ref:** #1 The Evidence Finding INTRODUCTION: Patients with autosomal dominant polycystic kidney disease (ADPKD) often develop early vascular stiffening and hypertension. Dietary sodium may worsen vascular stiffness via epithelial sodium channel (ENaC) activation, and ENaC inhibition might mitigate this, but this remains untested in ADPKD. We hypothesized that… What’s up, Doc? Strictly limit dietary sodium in early-stage ADPKD to preserve arterial elasticity. When treating hypertension, consider amiloride to specifically block ENaC-mediated vascular stiffening and reduce long-term cardiovascular risk. Read More: Clinical Deep Dive & Synthesis Arterial remodeling in autosomal dominant polycystic kidney disease (ADPKD) represents far more than an incidental downstream consequence of parenchymal cyst expansion; it is an intrinsic, early-onset vasculopathy driven by genetic and biophysical derangements. Mutations in *PKD1* or *PKD2*, encoding polycystin-1 and polycystin-2 respectively, directly destabilize endothelial primary cilia architecture and perturb shear-stress-mediated calcium influx. In young adult patients presenting with preserved filtration capacity—defined here as an estimated glomerular filtration rate (eGFR) of 60 ml/min or greater—this baseline cellular defect manifests as premature arterial stiffening and blunted flow-mediated dilation long before overt nephron dropout occurs. The introduction of excessive dietary sodium acts as a profound biological accelerant, transforming a latent genetic susceptibility into active vascular pathology by amplifying mechanical tension across the central elastic arteries and escalating carotid-femoral pulse wave velocity (cfPWV). The molecular bridge linking high luminal sodium to vascular structural rigidity resides in non-epithelial endothelial sodium channels (EnNaC). Composed of heterotrimeric $\alpha$-, $\beta$-, and $\gamma$-subunits, these vascular ENaC complexes serve as dynamic mechanosensors on the luminal endothelial membrane. Excess extracellular sodium concentrations trigger unchecked sodium influx through EnNaC, which directly induces hyperpolymerization of globular actin into a rigid subcortical filamentous actin (F-actin) web. This structural reorganization stiffens the endothelial cell cortex, preventing the physical deformation required to activate mechanosensitive endothelial nitric oxide synthase (eNOS, specifically phosphorylated at Ser1177). Concurrently, the intracellular sodium surge stimulates mitochondrial calcium extrusion through the mitochondrial sodium/calcium exchanger (NCLX), altering inner membrane potential and augmenting reactive oxygen species generation via NADPH oxidase. Uncoupled eNOS and elevated superoxide radicals swiftly scavenge the remaining bioavailable nitric oxide to form peroxynitrite, stripping the vascular smooth muscle of its primary tonic dilator, elevating vascular tone, and stiffening the macrovascular extracellular matrix. Amiloride intervenes directly within this pathobiological loop by functioning as a high-affinity, reversible pore blocker of ENaC. With a sub-micromolar inhibition constant ($K_i$ ranging from 0.1 to 0.5 $\mu$M for the $\alpha\beta\gamma$ heterotrimer), amiloride embeds deep within the extracellular vestibule of the channel, sterically obstructing ion permeation. From a pharmacokinetic perspective, amiloride exhibits a uniquely clean metabolic profile that bypasses hepatic biotransformation entirely. The molecule undergoes negligible Phase I oxidation and Phase II conjugation, displaying no measurable substrate, inducer, or inhibitor affinity for hepatic cytochrome P450 isoenzymes (including CYP3A4, CYP2D6, or CYP2C9). Following oral administration, it demonstrates an absolute bioavailability of roughly 50%, with systemic clearance governed primarily by the kidneys. Approximately half of the active drug is excreted unchanged in the urine via passive glomerular filtration coupled to active organic cation transporter 2 (OCT2) and multidrug and toxin extrusion (MATE) secretion in the proximal tubule. This absence of CYP-mediated clearance and drug-drug interactions provides a distinct translational advantage in ADPKD cohorts, who frequently require complex pharmacotherapeutic regimens to manage early secondary hypertension. At the level of cellular adaptation, this double-blind trial illustrates that pharmacologic blockade of ENaC preserves vascular elasticity despite the hostile biophysical milieu of a high-sodium challenge. Inhibiting endothelial sodium influx dissolves the rigid subcortical F-actin mesh, restores baseline cellular compliance, and reinstates fluid shear-stress-mediated eNOS activation, thereby preserving nitric oxide signaling to the underlying vascular smooth muscle. Clinically, blunting the sodium-induced surge in cfPWV decouples dietary salt indiscretions from accelerated microvascular shear injury, offering a mechanism-specific therapeutic buffer for individuals with intact renal reserve. By demonstrating that amiloride halts diet-induced vascular mechanical stiffening in ADPKD patients with preserved GFR, these findings shift our focus from late-stage gross hemodynamic control to early, targeted preservation of endothelial biomechanics, directly mitigating cardiovascular risk before irreversible medial elastocalcinosis and arteriolar fibrosis take root. Related CED Clinic Cornerstone Guide: [Mental Health & Neurological Disorders: Evidence-Based Clinical Frameworks →](https://cedclinic.com/mental-health-neurological-disorders/) Metabolic & Longevity Science 02 • TOP PRACTICE IMPACT LEVEL 1 EVIDENCE • 9.5/10 [External validation of artificial intelligence-guided electrocardiogram (AI-ECG) in detecting asymptomatic left ventricular dysfunction: A systematic review and meta-analysis.](https://doi.org/10.1016/j.ajpc.2026.101691?utm_source=weekly_review&utm_medium=ranked_feed&utm_campaign=2026-10-30&utm_content=rank2_external-validation-of-artificial-i) **Source:** American journal of preventive cardiology • **Ref:** #2 The Evidence Finding AIM: Asymptomatic left ventricular dysfunction (LVD) represents a key and frequently under-recognized stage in the heart failure (HF) continuum. Early identification enables targeted prevention and timely initiation of evidence-based therapies. Artificial intelligence-enabled electrocardiography (AI-ECG) may provide a scalable… What’s up, Doc? Robustly validated AI-ECG reliably detects asymptomatic left ventricular dysfunction. Leverage this scalable screening tool to trigger early echocardiography and initiate cardioprotective medical therapy well before overt heart failure emerges. Read More: Clinical Deep Dive & Synthesis When an otherwise stable patient presenting with metabolic syndrome, elevated ApoB, and visceral adiposity displays an unremarkable physical exam, a standard 12-lead tracing rarely triggers clinical alarm—until an externally validated AI-ECG algorithm flags a high probability of occult, asymptomatic left ventricular dysfunction. At this precise outpatient crossroads, the computational output must neither be dismissed as an algorithmic quirk nor managed with reflexive emergency referrals; it demands an immediate, stepped diagnostic cascade. My clinical decision-tree bypasses clinical inertia by reflexively ordering an outpatient transthoracic echocardiogram to objectively measure left ventricular ejection fraction and global longitudinal strain, coupled with serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin, and baseline cystatin-C-derived eGFR. Sitting knee-to-knee with the patient, I translate this artificial intelligence screen into clear, empowering language: "Your baseline tracing appears completely stable to the naked eye, but our algorithmic screen picked up micro-patterns that function like a silent smoke detector for subtle heart muscle fatigue, giving us a precious window to protect your heart long before you would ever feel short of breath." Once structural remodeling or an asymptomatic ejection fraction reduction (Stage B heart failure) is verified, the management protocol shifts decisively from watchful waiting to proactive cardiometabolic intervention. We begin with a rigorous deprescribing audit, pulling back fluid-retaining agents such as thiazolidinediones or chronic NSAIDs that frequently exacerbate subclinical ventricular strain. In their place, we initiate early-phase disease-modifying therapy: front-loading an SGLT2 inhibitor (such as empagliflozin 10 mg or dapagliflozin 10 mg daily) for its rapid reduction in ventricular filling pressures, favorable alteration of myocardial energetics, and renal tubular protection, regardless of whether type 2 diabetes is present. In patients carrying excess epicardial adipose volume, we carefully integrate a long-acting GLP-1 or dual GLP-1/GIP receptor agonist to drive visceral weight loss and quench systemic vascular inflammation. When micro-titrating an angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) or low-dose, vasodilating beta-blocker (such as carvedilol) into this regimen, I counsel the patient closely on self-monitoring of blood pressure and reassure them that a transient, non-progressive serum creatinine elevation of up to thirty percent reflects intraglomerular hemodynamic resetting rather than true structural kidney injury. Related CED Clinic Cornerstone Guide: [Medical Nutrition Therapy & Incretin Metabolism Framework →](https://cedclinic.com/medical-nutrition-therapy-hfpef-incretin-framework/) Medical Innovation & Clinical Tech 03 • PATIENT RESONANCE LEVEL 2 EVIDENCE • 9.2/10 [Evaluating a multi-vaccine respiratory immunization strategy involving SARS-CoV-2, pneumococcal, and influenza vaccines in adults: A randomized, open-label, multicenter, controlled, non-inferiority Phase IV trial in China.](https://doi.org/10.1080/21645515.2026.2747495?utm_source=weekly_review&utm_medium=ranked_feed&utm_campaign=2026-10-30&utm_content=rank3_evaluating-a-multi-vaccine-respirat) **Source:** Human vaccines & immunotherapeutics • **Ref:** #3 The Evidence Finding Co-administration of vaccines targeting multiple respiratory pathogens may enhance coverage and streamline adult immunization programs. We conducted a randomized, multicentre, open-label Phase IV trial registered at Chinese Clinical Trial Registry (ChiCTR2100046227) in China to evaluate the immunogenicity and safety of… What’s up, Doc? Deploy clinical AI strictly as an ambient cognitive assistant while maintaining non-negotiable human physician oversight at the bedside. Read More: Clinical Deep Dive & Synthesis Modern vaccinology too often falls into the trap of conflating administrative expediency with clinical efficacy, and this Phase IV trial of co-administered WIBP-CorV, PPV23, and IIV4 exemplifies that trend. By tethering its primary hypothesis to a statistical non-inferiority design based entirely on circulating humoral surrogates—specifically geometric mean titers (GMTs), seroconversion thresholds, and hemagglutination inhibition (HAI) titers—the investigation skips over the actual clinical endpoints that matter to a practicing physician: does this multi-antigen blitz actually prevent lower respiratory tract disease, hospitalization, and all-cause mortality? Polysaccharide responses driven by PPV23 operate primarily through T-cell-independent mechanisms that lack robust affinity maturation, while inactivated whole-virion SARS-CoV-2 vaccines and quadrivalent influenza formulations rely on distinct antigen presentation pathways to induce neutralizing immunoglobulins. Documenting non-inferior serum antibody concentrations twenty-eight days post-injection tells us remarkably little about durable cell-mediated immunity via CD4+ and CD8+ effector cascades, mucosal barrier protection, or memory B-cell longevity, ultimately mistaking a transient serological snapshot for sustained functional resilience. The immunological friction inherent in simultaneous administration also demands closer inspection, particularly given the specific biological composition of the platforms involved. Co-administering an aluminum hydroxide-adjuvanted inactivated virus alongside the heavy, multi-serotype polysaccharide burden of PPV23 risks epitope masking, adjuvant-driven cytokine skewing, and competition for microenvironmental niche space within draining lymph node germinal centers. Furthermore, the trial’s demographic partitioning—a crude binary split between adults aged 18–59 and those aged 60 and older within a geographically and ethnically homogenous Chinese cohort—obscures the pronounced phenotypic variations of clinical immunosenescence. Grouping a robust 61-year-old with an 85-year-old harboring baseline cardiovascular disease, blunted thymic output, and altered T-cell receptor diversity invalidates the assumption of uniform non-inferiority across the geriatric spectrum. By failing to stratify for baseline metabolic dysregulation, systemic inflammation, or subclinical frailty, the authors homogenize a population whose real-world physiological responses to a dense antigenic challenge are notoriously divergent. The open-label methodology introduces an undeniable vulnerability to reporting bias, particularly regarding subjective reactogenicity endpoints like fatigue, arthralgia, and systemic malaise. When both patients and evaluators are acutely aware that three distinct immunizations are being delivered concurrently, psychoneuroimmunologic expectations and differential reporting vigilance inevitably warp the safety profile. For the clinician balancing holistic patient vitality against preventive guidelines, the allure of an all-in-one visit must be weighed against functional recovery: a patient incapacitated by cumulative reactogenicity for seventy-two hours has not experienced an unmitigated clinical success simply because their clinic visits were consolidated. Until trial endpoints pivot to reflect authentic patient health—evaluating mucosal secretory IgA kinetics, preservation of baseline functional status, and verified protection against clinical respiratory failure—we must treat surrogate non-inferiority not as a green light for aggressive poly-immunization, but as an abstracted immunologic signal that has yet to prove its real-world translation. Related CED Clinic Cornerstone Guide: [How to Read a Cannabis COA: Lab Safety & Data Verification →](https://cedclinic.com/how-to-read-a-cannabis-coa/) Cannabinoid Science & ECS 04 • FRONTIER WILDCARD EXPLORATORY • 9.0/10 [DIalysis Symptom COntrol-Pruritus Outcome Trial (DISCO-POT): A Multicenter Randomized Blinded Placebo Controlled Crossover Trial.](https://doi.org/10.1016/j.xkme.2026.101451?utm_source=weekly_review&utm_medium=ranked_feed&utm_campaign=2026-10-30&utm_content=rank4_dialysis-symptom-control-pruritus-o) **Source:** Kidney medicine • **Ref:** #4 The Evidence Finding RATIONALE & Uremic pruritus affects up to 50% of patients with kidney failure and negatively impacts quality of life. Itch often persists and remains insufficiently controlled despite standard of care treatments. We evaluated the effects of nabilone, a synthetic cannabinoid, in patients with kidney failure receiving dialysis who had… What’s up, Doc? Nabilone fails to outperform placebo for uremic pruritus and introduces avoidable neurocognitive side effects. Clinicians should bypass synthetic cannabinoids here and rely on proven, guideline-directed antipruritic therapies for dialysis patients. Read More: Clinical Deep Dive & Synthesis The clinical presentation of uremic pruritus represents far more than an uncomfortable dermatologic sequela of kidney failure; it is an overt manifestation of profound systemic, neuro-immune, and metabolic breakdown. In the Dialysis Symptom Control-Pruritus Outcome Trial (DISCO-POT), investigators evaluated the synthetic cannabinoid nabilone via a multicenter, randomized, blinded, placebo-controlled crossover design in patients maintained on hemodialysis or peritoneal dialysis. This methodology is particularly robust for an intractable symptom like chronic itch, as crossover trials leverage patients as their own controls to account for the massive intra-individual variability inherent to end-stage renal disease (ESRD). Conventional treatments—ranging from topical emollients to antihistamines and phototherapy—routinely fall short because they fail to engage the complex, deep-seated neuro-inflammatory networks driving uremic itch. By intervening with an exogenous cannabinoid, the trial directly probed whether stabilizing the endocannabinoid system (ECS) could offer relief where standard membrane clearance and dialytic regimens perpetually fail. Targeting this refractory pathology demands an appreciation of the bidirectional signaling pathways operating across the skin, peripheral nerves, and central nervous system. Nabilone acts as an agonist at both cannabinoid type 1 (CB1) and type 2 (CB2) receptors, engaging critical biological checkpoints that govern pruriceptive signaling. Cutaneously, CB2 receptor activation on keratinocytes and mast cells tempers the transcription and release of key pro-pruritic and pro-inflammatory mediators, notably interleukin-31 (IL-31), tumor necrosis factor-alpha (TNF-α), and nerve growth factor. Concurrently, CB1 agonism on unmyelinated primary afferent C-fibers attenuates presynaptic depolarization and blunts the antidromic release of substance P and calcitonin gene-related peptide. Furthermore, dynamic cross-talk between the ECS and transient receptor potential vanilloid 1 (TRPV1) channels promotes functional desensitization of peripheral itch receptors, preventing the pathological amplification of cutaneous signals that otherwise project unchecked up the spinothalamic tract to sensory cortices. Viewing this trial through the prism of multi-axis longevity reveals that uremic pruritus is deeply entangled with cardiometabolic strain and vascular stiffness. Chronic kidney failure is inextricably linked to accelerated vascular calcification, secondary hyperparathyroidism, and heightened pulse wave velocity, which together signify severe arterial stiffening. The relentless sensory insult of chronic itch triggers sustained sympathetic overdrive, elevating nocturnal catecholamines and disrupting autonomic balance as reflected by blunted heart rate variability (HRV). This non-dipping nocturnal autonomic profile accelerates endothelial dysfunction, compounding the atherogenic milieu characterized by elevated apolipoprotein B (ApoB) and remnants of small dense lipoproteins. Simultaneously, continuous hypercortisolemia driven by unremitting physical distress exacerbates peripheral insulin resistance, demonstrable through erratic continuous glucose monitoring tracings and skewed homeostatic model assessment (HOMA-IR) values even in non-diabetic dialysis cohorts. The systemic downstream consequences of unmanaged pruritus intersect directly with protein-energy wasting (PEW) and progressive sarcopenia. The debilitating sleep fragmentation caused by nocturnal itch fundamentally destroys restorative slow-wave architecture, an endocrine window vital for growth hormone secretion and tissue repair. Over time, this chronic neuro-endocrine disruption shifts the balance toward unchecked systemic catabolism, accelerating the loss of appendicular lean mass index as quantified by dual-energy X-ray absorptiometry (DXA). Loss of functional skeletal muscle mass in ESRD is one of the strongest independent predictors of all-cause mortality, creating a vicious cycle of physical frailty, systemic microinflammation, and diminished biological reserve. Therapeutic interventions with agents like nabilone must therefore be evaluated not merely through visual analog scale reductions in itch, but through their downstream capacity to preserve lean mass, safeguard metabolic sinks, and halt the catabolic spiral precipitated by systemic sleep deprivation. Translating the DISCO-POT findings into sophisticated clinical practice requires nuanced patient selection, precise dose titration, and integration with multimodal lifestyle levers. Synthetic cannabinoid therapy carries central nervous system liabilities, including somnolence and cognitive blunting, which must be scrupulously weighed against the existing baseline of uremic encephalopathy and polypharmacy. Clinical strategies should deliberately pair low-dose, individualized ECS modulation with supportive interventions: aggressive optimization of dialysate temperatures to mitigate post-treatment cutaneous vasodilation, lipid-barrier repair using topicals rich in physiological ceramides or palmitoylethanolamide, and targeted nutritional programming to support the depleted gut-brain axis without overloading potassium or phosphate limits. By approaching uremic pruritus not as an isolated symptom, but as a node within an interconnected neuro-vascular-metabolic matrix, clinicians can leverage targeted cannabinoid therapies to quiet pathological signaling, defend body composition, and meaningfully alter the longevity trajectory of patients with end-stage renal failure. Related CED Clinic Cornerstone Guide: [Deep Dive: The Expanded Endocannabinoid System →](https://cedclinic.com/deep-dive-the-expanded-endocannabinoid-system/) [https://cedclinic.com/ask](https://cedclinic.com/ask) Try Asking:[💤Sleep & REM](https://cedclinic.com/ask)[🌱CBG & Gut](https://cedclinic.com/ask)[⚡GLP-1 & ECS](https://cedclinic.com/ask)[👵Micro-Titration](https://cedclinic.com/ask) Dr. Caplan’s Integrative Clinical Perspective Modern medical progress stalls when specialties operate in silos. Metabolic health directly dictates neurocognitive resilience; endocannabinoid tone modulates gut and pain pathways; and preventive primary care requires deprescribing and circadian alignment just as much as new prescriptions. As new research emerges weekly, our focus remains steadfast on patient-centered precision: connecting verified molecular mechanisms to sustainable clinical health. Explore our ongoing translational syntheses in the [CED Clinic Clinical Insights Library](https://cedclinic.com/clinical-insights-applications/). Standard Clinical Care Personalized Outpatient Medical Care Direct physician-guided evaluations for medical cannabis certifications, incretin metabolism protocols, preventive longevity, and personalized micro-titration. [Book Patient Consultation →](https://cedclinic.com/schedule-an-appointment/) High-Acuity Advisory Executive Medical Quarterbacking Bespoke clinical navigation for complex polypharmacy, refractory multi-system diagnostic dilemmas, physician curbside consultations, and discreet private advisory. [Request Private Case Advisory →](https://cedclinic.com/private-consultation/) #### Verified References & Trackable Literature - [Randomized Controlled Trial of Salt and Amiloride on Vascular Stiffness in ADPKD.](https://doi.org/10.1016/j.ekir.2026.107110?utm_source=weekly_review&utm_medium=ranked_feed&utm_campaign=2026-10-30&utm_content=rank1_randomized-controlled-trial-of-salt) — *Kidney international reports*. - [External validation of artificial intelligence-guided electrocardiogram (AI-ECG) in detecting asymptomatic left ventricular dysfunction: A systematic review and meta-analysis.](https://doi.org/10.1016/j.ajpc.2026.101691?utm_source=weekly_review&utm_medium=ranked_feed&utm_campaign=2026-10-30&utm_content=rank2_external-validation-of-artificial-i) — *American journal of preventive cardiology*. - [Evaluating a multi-vaccine respiratory immunization strategy involving SARS-CoV-2, pneumococcal, and influenza vaccines in adults: A randomized, open-label, multicenter, controlled, non-inferiority Phase IV trial in China.](https://doi.org/10.1080/21645515.2026.2747495?utm_source=weekly_review&utm_medium=ranked_feed&utm_campaign=2026-10-30&utm_content=rank3_evaluating-a-multi-vaccine-respirat) — *Human vaccines & immunotherapeutics*. - [DIalysis Symptom COntrol-Pruritus Outcome Trial (DISCO-POT): A Multicenter Randomized Blinded Placebo Controlled Crossover Trial.](https://doi.org/10.1016/j.xkme.2026.101451?utm_source=weekly_review&utm_medium=ranked_feed&utm_campaign=2026-10-30&utm_content=rank4_dialysis-symptom-control-pruritus-o) — *Kidney medicine*. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).